Latest News and Press Releases

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA),...

EXTON, Pa. and CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery,...

EXTON, Pa. and CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Feb. 19, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced they will...

Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12Under the Securities Exchange Act of 1934Subject Company: Idera...

EXTON, Pa. and CAMBRIDGE, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...

- Available Translational Data Continue to Demonstrate Correlation between Proliferation and Clonal Expansion of T-Cells to Clinical Responses - - An additional 5th Unconfirmed RECIST v1.1 Response...

– IMO 2125 Translational Data Update at SITC on November 11 –– Completes Public Offering, extends runway into second quarter 2019 – CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Idera...